Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AST2169 liposome
- Development stage
- Unknown
- Lead developer
- Allist Pharmaceuticals, Inc.
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
AST2169 liposome is an investigational, liposome-formulated selective small molecule inhibitor of the KRAS G12D mutant protein, developed by Allist Pharmaceuticals. The KRAS G12D mutation is a highly prevalent oncogenic driver found in various cancers, including pancreatic, colorectal, and non-small cell lung cancers. By encapsulating the selective KRAS G12D inhibitor in a liposomal delivery system, AST2169 liposome is designed to improve tumor targeting, enhance penetration, and reduce off-target toxicities. It is currently undergoing Phase 1 clinical evaluation in patients with KRAS G12D-mutant advanced solid tumors.
- Other names
- AST2169 liposome for injectionAST-2169 liposome for injectionAST 2169 liposome for injectionAST2169 liposome injectionAST-2169 liposome injectionAST 2169 liposome injection注射用AST2169脂质体
02
Targets
KRASG12D (Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutant)
Beyond the preview
Go deeper on AST2169 liposome.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AST2169 liposome.